Abrilada
Product Images NDC 0069-0347

Product Visual Gallery

This gallery contains 42 technical images submitted to the FDA as part of the official labeling for Abrilada (NDC 0069-0347). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Abrilada 01)

A line graph depicting the percent of ACR20 responders over time (weeks) comparing two groups: one receiving 40 mg every other week and the other receiving a placebo. The graph shows higher response percentages for the 40 mg group throughout the 48-week period, with percent responders peaking around 24 weeks.*

FDA Label Image

Figure 2 (Abrilada 02)

A line chart showing the percentage of ASAS 20 Response over time (weeks) for two groups: Placebo (N=107) represented by a dashed line with circles, and Adalimumab (N=208) represented by a solid line with squares. The graph depicts higher response rates over 24 weeks for Adalimumab compared to placebo.*

FDA Label Image

Study Uv I (Abrilada 02a)

A line graph showing treatment failure rate over time in months, comparing three groups: Treatment, Placebo, and Adalimumab. The y-axis represents the treatment failure rate percentage, and the x-axis shows time in months up to 20. The lines indicate different rates of treatment failure among the groups, with Placebo showing the highest failure rate and Adalimumab the lowest over the period.*

FDA Label Image

Study Uv Ii (Abrilada 02b)

A line graph displaying treatment failure rates (%) over time (months) comparing three groups: Treatment, Placebo, and Adalimumab. The X-axis shows time in months from 0 to 20, and the Y-axis shows treatment failure rate percentage from 0 to 100. The graph visually compares efficacy over the study period.*

FDA Label Image

Pfizer (Abrilada 03)

FDA Label Image

Pfizer (Abrilada 04)

FDA Label Image

Step 3 (Abrilada 05)

An instructional illustration labeled Step 3 showing a hand holding a medication device, focusing on checking the medicine and expiration date through a transparent window on the device. This is part of usage instructions for ABRILADA by Pfizer Laboratories Div Pfizer Inc.*

FDA Label Image

Image (Abrilada 06)

An instructional diagram showing parts of the ABRILADA injection device. The labeled components include the cap, window, injection button, and expiration date on the device. A magnified section highlights the location of the expiration date near the injection button.*

FDA Label Image

Step 4 (Abrilada 07)

An instructional illustration showing where to choose and prepare the injection site for ABRILADA. It highlights the abdomen area, advising to keep at least 2 inches (5 cm) away from the belly button, and the front upper thigh as appropriate injection sites.*

FDA Label Image

Step 5 (Abrilada 08)

An instructional illustration labeled 'Step 5 Remove the cap' showing a hand removing the cap from a pen injector device. A red arrow indicates the direction to pull the cap away from the main body of the pen.*

FDA Label Image

C:\temp\pfizer Oct 4\attached File _1664891496641_2578536_2022_09_20_81a33cfa-262f_11027\abrilada-09.jpg (Abrilada 09)

An instructional diagram labeled Step 6, titled 'Insert the needle.' It shows a hand holding a syringe with an arrow indicating the needle being pushed down. Two small circular insets illustrate a close-up view of the needle assembly from different angles, emphasizing the downward push action required to insert the needle.*

FDA Label Image

Step 7 (Abrilada 10)

An instructional diagram illustrating step 7 for injecting medicine with a device. It shows three stages: pressing the device until a first click, keeping it held until a second click occurs, and then waiting while holding the device for 5 more seconds to complete the injection.*

FDA Label Image

Step 8 (Abrilada 11)

Illustration showing step 8 of a procedure, titled 'Check the window.' It depicts a hand holding a device, focusing on a small window area colored red and gray, likely for visual confirmation or verification during use.*

FDA Label Image

Step 9 (Abrilada 12)

Instructional diagram showing Step 9 of a process involving a prefilled pen injector. It depicts a hand firmly gripping the pen and pulling it upward to remove it, indicated by a red upward arrow below the pen. The step is labeled 'Remove the pen.'*

FDA Label Image

Step 10 (Abrilada 13)

Instructional illustration showing the disposal step of a used pen device. It depicts a hand holding the pen above a disposal container with a lid, focusing on safe disposal procedure, labeled as Step 10.*

FDA Label Image

Step 11 (Abrilada 14)

An instructional illustration labeled "Step 11" showing a hand wiping the skin with a cotton ball or swab after an injection. This is part of a step-by-step guide for post-injection care.*

FDA Label Image

Image (Abrilada 15)

Instructional illustration showing two methods for preparing a subcutaneous injection site. On the left, the stretch method is demonstrated with fingers pulling the skin taut. On the right, the pinch method is depicted with fingers lifting a fold of skin. This diagram is associated with ABRILADA, a product by Pfizer Laboratories Div Pfizer Inc.*

FDA Label Image

Pfizer (Abrilada 16)

FDA Label Image

Image (Abrilada 17)

An instructional diagram of a prefilled autoinjector syringe for ABRILADA, showing labeled parts including the plunger rod, barrel, window, needle cover, and the expiration date area on the syringe body.*

FDA Label Image

Step 3 (Abrilada 18)

Instructional illustration showing Step 3 of unpacking a prefilled syringe from its tray, with a hand lifting the syringe straight upward out of its molded packaging.*

FDA Label Image

Step 4 (Abrilada 19)

An instructional illustration showing a hand holding a vial with the text 'Step 4 Check your medicine and expiration date', highlighting the importance of verifying the medication and its expiration before use.*

FDA Label Image

Step 5 (Abrilada 20)

An instructional diagram labeled Step 5, showing a simplified human figure highlighting recommended injection sites for ABRILADA. The abdomen area is marked with instructions to keep injections at least 2 inches (5 cm) away from the belly button. The front upper thigh regions are also indicated as injection sites.*

FDA Label Image

Step 6 (Abrilada 21)

An instructional illustration labeled Step 6 shows how to remove the needle cover from a syringe by pulling it upward. The image depicts two hands holding the syringe and the needle cover, guiding the removal process for ABRILADA injection preparation.*

FDA Label Image

Step 7 (Abrilada 22)

An instructional illustration showing Step 7 for administering an injection of ABRILADA. It depicts a hand holding the needle at a 45-degree angle to the skin surface, guiding the needle insertion for subcutaneous injection.*

FDA Label Image

Step 8 (Abrilada 23)

An instructional illustration labeled Step 8 showing a hand holding a syringe with an arrow indicating the direction to inject the medicine from the syringe needle. The image is part of a step-by-step guide for medicine injection.*

FDA Label Image

Step 9 (Abrilada 24)

An instructional illustration labeled Step 9 titled 'Check your syringe' showing a close-up of a hand holding a syringe with a visible needle and vial attachment. The image focuses on verifying the syringe before use, part of a step-by-step guidance.*

FDA Label Image

Step 10 (Abrilada 25)

An instructional illustration depicting step 10 in the disposal process of a used syringe. The image shows a hand holding a syringe, disposing of it into a designated sharps container. The label "Dispose of used syringe" is shown with an arrow indicating the action.*

FDA Label Image

Step 11 (Abrilada 26)

Step 11 of an instructional diagram shows a hand holding a cotton ball or pad, which is being used to apply or remove a substance. The background is gray, and the word 'After' is displayed near the step number.*

FDA Label Image

Pfizer (Abrilada 27)

FDA Label Image

Principal Display Panel (0.8 mL Prefilled Pen Label)

The label for ABRILADA (adalimumab-afzb) Injection, 40 mg/0.8 mL, a citrate-free single-dose prefilled pen for subcutaneous injection. Manufactured and distributed by Pfizer Laboratories Division Pfizer Inc. Storage instructions specify refrigeration at 36°F to 46°F (2°C to 8°C), with no freezing and protection from light. Dosage information directs users to see prescribing information.*

FDA Label Image

Principal Display Panel (Kit Carton)

Packaging label for ABRILADA (adalimumab-afzb) injection, 40 mg/0.8 mL, citrate-free, by Pfizer Laboratories Div Pfizer Inc. The carton contains two single-dose prefilled pens for subcutaneous injection, including prefilled pens, alcohol preps, a package insert, and instructions for use. Storage and usage instructions are included on the label.*

FDA Label Image

Principal Display Panel (0.8 mL Syringe Label)

Abrilada 40 mg/0.8 mL injection label showing the drug name with active ingredient adalimumab-afzb for subcutaneous injection. The label indicates single-dose use, manufactured by Pfizer Inc., New York, NY. Also visible are the NDC number (0069-0317-01), barcode, and space for lot and expiration dates.*

FDA Label Image

Principal Display Panel (0.8 mL Syringe Tray Label)

Label for Abrilada (adalimumab-afzb) Injection 40 mg/0.8 mL, a single-dose prefilled syringe for subcutaneous injection. The label states citrate-free and no preservative. Manufactured by Pfizer Inc, New York, NY, with instructions for storage and handling, including refrigeration requirements and expiration warnings.*

FDA Label Image

Principal Display Panel (Kit Carton)

Carton packaging for ABRILADA (adalimumab-afzb) injection, citrate-free, 40 mg/0.8 mL. The label indicates two single-dose prefilled syringes for subcutaneous injection only. The carton includes instructions such as storage conditions, contents of the package, and manufacturer Pfizer Laboratories Div Pfizer Inc.*

FDA Label Image

Principal Display Panel (0.4 mL Syringe Label)

Label for ABRILADA (adalimumab-afzb) Injection, 20 mg/0.4 mL, intended for subcutaneous injection only. The label indicates single-dose use, includes an NDC number (0069-0329-01), and shows it is distributed by Pfizer Laboratories Div Pfizer Inc in NY, NY. The label displays space for lot and expiration dates and includes barcode and QR code elements.*

FDA Label Image

Principal Display Panel (0.4 mL Syringe Tray Label)

Packaging label for ABRILADA (adalimumab-afzb) Injection, 20 mg per 0.4 mL citrate-free prefilled syringe. Single-dose for subcutaneous injection, no preservative. Label shows manufacturer Pfizer Laboratories Div Pfizer Inc, New York, NY, with storage instructions and barcode. The label is designed with white background, blue and pink accents.*

FDA Label Image

Principal Display Panel (Kit Carton)

Abrilada (adalimumab-afzb) Injection 20 mg/0.4 mL carton label by Pfizer Laboratories Div Pfizer Inc. The package contains two single-dose prefilled syringes for subcutaneous injection, including alcohol preps and instructions for use. The label states citrate-free formulation, storage instructions, and cautions such as 'Do not shake' and 'Keep out of reach of children.'*

FDA Label Image

Principal Display Panel (0.2 mL Syringe Label)

The label for ABRILADA (adalimumab-afzb) Injection shows 10 mg/0.2 mL dosage for subcutaneous injection. It is a single-dose product labeled for Rx only by Pfizer Laboratories Div Pfizer Inc. The label includes an NDC number, barcode, and a note about a transparent laser reactive coating area for variable data.*

FDA Label Image

Principal Display Panel (0.2 mL Syringe Tray Label)

Packaging label for ABRILADA (adalimumab-afzb) Injection, 10 mg/0.2 mL, a single-dose prefilled syringe for subcutaneous injection. The label indicates no preservative, is marked Rx only, and is manufactured by Pfizer Laboratories Div Pfizer Inc. Storage instructions and handling warnings are also included on the label.*

FDA Label Image

Principal Display Panel (Kit Carton)

Packaging label for Abrilada (adalimumab-afzb) Injection 10 mg/0.2 mL by Pfizer Laboratories Div Pfizer Inc. The carton contains two single-dose prefilled syringes for subcutaneous injection only. The label includes product storage instructions, contents such as alcohol swabs and medication guide, and a visual of a syringe.*

FDA Label Image

Principal Display Panel (0.8 mL Vial Label)

Label for ABRILADA (adalimumab-afzb) Injection, 40 mg/0.8 mL, a single-dose vial for subcutaneous injection. The label indicates storage at 2°C to 8°C, discard unused portion, and is manufactured by Pfizer Inc, New York, NY. It includes spaces for lot number and expiration date.*

FDA Label Image

Principal Display Panel (0.8 mL Vial Carton)

Packaging label for Abrilada (adalimumab-afzb) Injection 40 mg/0.8 mL, a single-dose vial for subcutaneous injection. The label states it is for institutional use only, contains no preservatives, and should not be shaken. Storage instructions include refrigeration at 36° to 46°F and protection from light. Manufactured and distributed by Pfizer Laboratories Div Pfizer Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.